These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33837665)

  • 1. Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
    Castillo-Ecija H; Pascual-Pasto G; Perez-Jaume S; Resa-Pares C; Vila-Ubach M; Monterrubio C; Jimenez-Cabaco A; Baulenas-Farres M; Muñoz-Aznar O; Salvador N; Cuadrado-Vilanova M; Olaciregui NG; Balaguer-Lluna L; Burgueño V; Vicario FJ; Manzanares A; Castañeda A; Santa-Maria V; Cruz O; Celis V; Morales La Madrid A; Garraus M; Gorostegui M; Vancells M; Carrasco R; Krauel L; Torner F; Suñol M; Lavarino C; Mora J; Carcaboso AM
    J Pathol Clin Res; 2021 Jul; 7(4):338-349. PubMed ID: 33837665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
    Nanni P; Landuzzi L; Manara MC; Righi A; Nicoletti G; Cristalli C; Pasello M; Parra A; Carrabotta M; Ferracin M; Palladini A; Ianzano ML; Giusti V; Ruzzi F; Magnani M; Donati DM; Picci P; Lollini PL; Scotlandi K
    Sci Rep; 2019 Aug; 9(1):12174. PubMed ID: 31434953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
    Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
    Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
    Chen Y; Zhang R; Wang L; Correa AM; Pataer A; Xu Y; Zhang X; Ren C; Wu S; Meng QH; Fujimoto J; Jensen VB; Antonoff MB; Hofstetter WL; Mehran RJ; Pisimisis G; Rice DC; Sepesi B; Vaporciyan AA; Walsh GL; Swisher SG; Roth JA; Heymach JV; Fang B
    Cancer; 2019 Nov; 125(21):3738-3748. PubMed ID: 31287557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing.
    Cornillie J; Wozniak A; Li H; Wang Y; Boeckx B; Gebreyohannes YK; Wellens J; Vanleeuw U; Hompes D; Stas M; Sinnaeve F; Wafa H; Lambrechts D; Debiec-Rychter M; Sciot R; Schöffski P
    Mol Cancer Ther; 2019 Jun; 18(6):1168-1178. PubMed ID: 30962320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma.
    Aschero R; Castillo-Ecija H; Baulenas-Farres M; Resa-Pares C; Jimenez-Cabaco A; Rodriguez E; Monterrubio C; Perez-Jaume S; Suñol M; Chantada GL; Lavarino C; Mora J; Carcaboso AM
    Pediatr Blood Cancer; 2023 Jun; 70(6):e30318. PubMed ID: 36973999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
    Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
    J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers.
    Moon HG; Oh K; Lee J; Lee M; Kim JY; Yoo TK; Seo MW; Park AK; Ryu HS; Jung EJ; Kim N; Jeong S; Han W; Lee DS; Noh DY
    Breast Cancer Res Treat; 2015 Nov; 154(1):13-22. PubMed ID: 26438141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
    Ju HY; Park M; Lee JA; Park HJ; Park SY; Kim JH; Kang HG; Yang HC; Park BK
    Cancer Res Treat; 2022 Apr; 54(2):563-571. PubMed ID: 34126703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer.
    Chen Q; Wei T; Wang J; Zhang Q; Li J; Zhang J; Ni L; Wang Y; Bai X; Liang T
    Pancreatology; 2020 Apr; 20(3):485-492. PubMed ID: 32113935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ewing Sarcoma PDX Models.
    Surdez D; Landuzzi L; Scotlandi K; Manara MC
    Methods Mol Biol; 2021; 2226():223-242. PubMed ID: 33326106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.
    Pascual-Pasto G; Resa-Pares C; Castillo-Ecija H; Aschero R; Baulenas-Farres M; Vila-Ubach M; Burgueño V; Balaguer-Lluna L; Cuadrado-Vilanova M; Olaciregui NG; Martinez-Velasco N; Perez-Jaume S; de Alava E; Tirado OM; Lavarino C; Mora J; Carcaboso AM
    Biochem Pharmacol; 2023 Feb; 208():115408. PubMed ID: 36603685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
    Yu PY; Gardner HL; Roberts R; Cam H; Hariharan S; Ren L; LeBlanc AK; Xiao H; Lin J; Guttridge DC; Mo X; Bennett CE; Coss CC; Ling Y; Phelps MA; Houghton P; London CA
    PLoS One; 2017; 12(7):e0181885. PubMed ID: 28750090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
    Mora J; Cruz CO; Parareda A; de Torres C
    J Pediatr Hematol Oncol; 2009 Oct; 31(10):723-9. PubMed ID: 19727011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
    Harrison DJ; Gill JD; Roth ME; Zhang W; Teicher B; Erickson S; Gatto G; Kurmasheva RT; Houghton PJ; Smith MA; Kolb EA; Gorlick R
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28222. PubMed ID: 32207565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas.
    Pascual-Pasto G; Castillo-Ecija H; Unceta N; Aschero R; Resa-Pares C; Gómez-Caballero A; Vila-Ubach M; Muñoz-Aznar O; Suñol M; Burgueño V; Gomez-Gonzalez S; Sosnik A; Ibarra M; Schaiquevich P; de Álava E; Tirado OM; Mora J; Carcaboso AM
    J Control Release; 2022 Feb; 342():81-92. PubMed ID: 34974029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
    Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
    Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
    Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
    Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment Neutrophil-to-Lymphocyte Ratio and Lymphocyte Recovery: Independent Prognostic Factors for Survival in Pediatric Sarcomas.
    Vasquez L; León E; Beltran B; Maza I; Oscanoa M; Geronimo J
    J Pediatr Hematol Oncol; 2017 Oct; 39(7):538-546. PubMed ID: 28697168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thioredoxin Reductase Inhibitor Suppresses the Local Progression of Rhabdomyosarcoma With PDX Models.
    Kinoshita H; Kinoshita S; Kamoda H; Hagiwara Y; Ohtori S; Yonemoto T
    Cancer Genomics Proteomics; 2024; 21(2):178-185. PubMed ID: 38423598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.